REVIEW ARTICLE |
|
Year : 2019 | Volume
: 32
| Issue : 1 | Page : 1-7 |
|
Platelet-derived growth factor in patients with liver fibrosis
Enas S Essa1, Fikry G Eskander2, Amira Z Badawy1
1 Clinical Pathology Department, Faculty of Medicine, Menoufia University, Shebeen El-Kom, Egypt 2 Clinical Pathology Department, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
Correspondence Address:
Amira Z Badawy Clinical Pathology Department, Faculty of Medicine, Menoufia University, Shebeen El-Kom, Menoufia Governorate Egypt
Source of Support: None, Conflict of Interest: None | Check |
DOI: 10.4103/mmj.mmj_468_17
|
|
Objective
To asses the changes in platelet-derived growth factor (PDGF) in liver fibrosis.
Data sources
The data were sourced from the PubMed database from the start of the database to 2017 and from all materials available in the Internet.
Study selection
The initial search presented 423 articles of which 39 met the inclusion criteria. The articles studied the relation between PDGF and liver fibrosis.
Data extraction
If the studies did not fulfill the inclusion criteria, they were excluded. Study quality assessment included when ethical approval was obtained, eligibility criteria defined, sufficient information, convenient controls, and known assessment measures.
Data synthesis
Comparisons were made through structured review with the results tabulated.
Findings
In total, 39 potentially relevant publications were included. The studies indicate an association between PDGF and liver fibrosis as PDGF increases in patients with hepatic fibrosis and correlates well with the grade of fibrosis. The majority of studies were performed on the effect of PDGF antagonists on liver fibrosis and they found that interference of PDGF pathway leads to reduction of liver fibrosis.
Conclusion
We found that PDGF levels increase in patients with liver fibrosis and its level correlates well with the stage of fibrosis; thus, PDGF can be used as a potential noninvasive marker for liver fibrosis either alone or in association with other fibrosis markers. Further, antagonizing the pathway of PDGF may offer a promising strategy for the treatment of liver fibrosis.
|
|
|
|
[FULL TEXT] [PDF]* |
|
|
|